During a Targeted Oncology live case-based peer perspectives live discussion, Anna C. Pavlick, DO, MS, explained to a group of physicians best practices for the diagnosis and management of patients with metastatic melanoma. Pavlick, co-director of the Melanoma Program and assistant director of the Clinical Research Education at NYU Perlmutter Cancer Center, discussed treatment options […]
Archive | Of Interest
Pavlick Covers Research in BRAF Wild-Type Metastatic Melanoma
Posted in Melanoma News, Health Professionals, Of Interest
Metabolic Imbalance Linked to Immune Checkpoint Inhibitor Resistance
According to a report by Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard, metabolic imbalance in some patients with cancer following treatment with the checkpoint inhibitor nivolumab is associated with resistance to the immunotherapy agent and shorter survival.
Posted in Melanoma News, Health Professionals, Of Interest
Harnessing the Power of Microbes to Fight Cancer
Probiotics, traditionally perceived to be good for the gut and overall health, may not be the best choice in patients with cancer.
Posted in Melanoma News, Health Professionals, Of Interest
Soluble PD-1 Is a Potential Biomarker in Metastatic Melanoma in Patients Treated With Autologous Vaccines
Research on programmed-death 1 (PD-1) found on T cells and its receptor, programmed-death ligand 1 (PD-L1), found in varying levels on tumor is a central topic in immunotherapy.
Posted in Melanoma News, Health Professionals, Of Interest
